-transparent.png){kind=logo}
Levamisole, L-2,3,5,6-tetrahydro-6-phenylimidazo-(2,1-b)-thiazole-hydrocholoride at various concentrations (2.5 to 40 microgram) added to platelet rich plasma inhibited aggregation of platelets. The 50% inhibition concentrations (IC50) of levamisole in platelet aggregation induced by hydrogen peroixde (9.4 x 10(-1) mM), epinephrine (1.0 x 10(-1) micrometer), endoperoxide-analog (2.9 x 10(-1) micrometer) and arachidonic acid (3.3 micrometer) were 11.0, 8.0, 11.5 and 16.0 microgram/test, respectively. It is suggested that levamisole like imidazole inhibit platelet aggregation and this factor should be considered in the administration of levamisole, especially in cardiovascular diseases.
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
January 1985,
Voprosy meditsinskoi khimii,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
January 1968,
Life sciences,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
March 1972,
Nature: New biology,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
February 1974,
Biochemical pharmacology,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
January 1980,
Thrombosis research,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
September 1974,
Thrombosis research,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
May 1981,
Molecular pharmacology,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
February 1982,
Biochemical and biophysical research communications,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
December 1979,
European journal of pharmacology,
Y Hokama, and
A H Morita, and
M A Abad, and
B S Joyo, and
D A Uchida, and
G W Fischer
February 1999,
Bioscience, biotechnology, and biochemistry,
